Following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme.
For information, the company have highlighted that the relevant clinical study (OPINION, NCT03402841) is being conducted as a post-marketing commitment study for the European Medicines Agency (EMA), and will not result in any change to the current approved indication or reimbursement status for olaparib. Therefore, NICE has suspended this appraisal from its current work programme.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 6205 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 January 2023 | Suspended. Following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. For information, the company have highlighted that the relevant clinical study (OPINION, NCT03402841) is being conducted as a post-marketing commitment study for the European Medicines Agency (EMA), and will not result in any change to the current approved indication or reimbursement status for olaparib. Therefore, NICE has suspended this appraisal from its current work programme. |
| 23 February 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual